
Product Portfolio
Three non-invasive tests for the three major gynecologic cancers
One DNA methylation platform, three NMPA Class III registered IVDs — cervical, endometrial and ovarian cancer. Every test uses non-invasive sampling and is backed by published multi-center clinical data.
The portfolio
Pick the test that matches your clinical pathway
Comparison
Compare the three tests at a glance
Sensitivity and specificity are from the registered clinical trials. Registration numbers are NMPA Class III IVD registrations.
| Test | Cancer | Genes | Sample | Sensitivity | Specificity | NMPA registration |
|---|---|---|---|---|---|---|
| CISCER® | Cervical Cancer | PAX1 / JAM3 | Cervical exfoliated cells (non-invasive sampling) | 89.60% | 96.50% | 20233400253 |
| CISENDO® | Endometrial Cancer | CDO1 / CELF4 | Cervical exfoliated cells (non-invasive sampling) | 94.51% | 94.16% | 20243402610 |
| CISOVA® | Ovarian Cancer | CDO1 / HOXA9 | Peripheral blood cell-free DNA (non-invasive sampling) | 93.19% | 92.78% | 20253402443 |
Need the IFU, a distributor quote or a validation study?
Tell us your laboratory setup and intended use. We reply within 1–2 business days with documents, performance data and collaboration options.
- IFU and registration certificates
- Clinical performance summary
- Distributor and study collaboration terms
